-transparent.png){kind=logo}
Attention has focused on naloxone, an opiate receptor antagonist, because of its potential benefit in reversing neurological damage after acute cerebral ischemia. To evaluate the safety and possible efficacy of high-dose naloxone in ischemic stroke patients we planned a double blind pilot study. Between January 1989 and May 1990 24 patients were randomly assigned to the naloxone or placebo group according to age and neurological deficit. Naloxone was given in a loading dose of 5 mg/kg over 10 minutes followed by a 24-hour infusion at the rate of 3.5 mg/kg/h. 10 patients experienced minor side effects but none of them had to discontinue the treatment. 9 patients improved: 6 in the naloxone group and 3 in the placebo group, but no significant difference was found using the non parametric Mann-Whitney test. Our study suggests that naloxone is safe at the dose used, but the results do not support the planning of similar trials on a larger scale.
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
January 1984,
Stroke,
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
January 2011,
Cerebrovascular diseases (Basel, Switzerland),
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
August 1995,
Stroke,
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
July 1994,
Stroke,
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
February 2003,
Stroke,
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
July 1995,
Stroke,
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
September 1995,
Annals of the New York Academy of Sciences,
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
January 2001,
European journal of neurology,
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
November 1990,
Age and ageing,
F Federico, and
V Lucivero, and
P Lamberti, and
A Fiore, and
C Conte
August 2015,
Gastroenterology,
